[RM1]Dr. Stern asked for “Comprised by” but comprised is a tricky word (I would typically say “comprised of,” but that’s also questionable), so can we change this to “Composed of”?
- Brings you up-to-date information on key topics in the field, including the application of anticonvulsants, anxiolytics, mood stabilizers, and psychostimulants; drug-drug interactions; side effects; treatment adherence; and more.
- Includes detailed coverage of antidepressants, antipsychotics, and antianxiety medications, as well as advances in caring for patients with treatment-resistant depression and new legal considerations when prescribing psychotropics.
- Covers recent progress on the use of neurotherapeutic interventions, such as transcranial magnetic stimulation, vagal nerve stimulation, and deep brain stimulation.
- Contains a new chapter on the pharmacotherapy of movement disorders (derived from Stern et al.’s MGH Handbook of General Hospital Psychiatry, 8th Edition).
- Features a user-friendly, highly templated format with abundant boxed summaries, bulleted points, case histories, algorithms, updated references, and suggested readings.
- Offers updated DSM-5-TR criteria alongside peerless, hands-on advice from members of the esteemed MGH Department of Psychiatry.
- An eBook version is included with purchase. The eBook allows you to access all of the text, figures, and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud. Additional digital ancillary content may publish up to 6 weeks following the publication date.
Includes clinical and research updates on:
- the application of a variety of medication classes (e.g., antidepressants, anticonvulsants, antipsychotics, anxiolytics, mood stabilizers, psychostimulants, psychedelics)
- advances in the treatment of treatment-resistant depression (e.g., the use of ketamine, electroconvulsive therapy, transcranial magnetic stimulation)
- progress on the use of neurotherapeutic interventions (e.g., vagal nerve stimulation, deep brain stimulation)
- legal considerations when prescribing psychotropics (e.g., informed consent, black box warnings)
Plus a new chapter on clinical and research applications of psychedelics
Authors
Theodore A. Stern Ned H. Cassem Professor of Psychiatry in the field of Psychosomatic Medicine/Consultation at Harvard Medical School; Chief Emeritus of The Avery D. Weisman, Psychiatry Consultation Service; and Director of the Thomas P. Hackett Center for Scholarship in Psychosomatic Medicine at the Massachusetts General Hospital.Dr. Theodore A. Stern is the Ned H. Cassem Professor of Psychiatry in the field of Psychosomatic Medicine/Consultation at Harvard Medical School (HMS), Chief Emeritus of The Avery D. Weisman, Psychiatry Consultation Service, and Director of the Thomas P. Hackett Center for Scholarship in Psychosomatic Medicine at the Massachusetts General Hospital (MGH). Dr. Stern has co-authored more than 550 peer-reviewed journal articles and book chapters, and he has edited or authored more than 60 books (including the MGH Handbook of General Hospital Psychiatry, the MGH Psychiatry Update and Board Preparation, Learning About Psychopharmacology, Facing Overweight and Obesity, Facing Pelvic Pain, Facing Memory Loss and Dementia, Facing Serious Mental Illness, and the MGH Study Guide for Psychiatry Exams). Dr. Stern is a Past-President of the Academy of Consultation-Liaison Psychiatry (ACLP) and is the Editor-in-Chief Emeritus of its journal, Psychosomatics (now called Journal of the Academy of Consultation-Liaison Psychiatry). He has won the coveted "Best Teacher Award� from the graduating residents at the MGH/McLean Hospital Psychiatric Residency Training Program, the Cynthia N. Kettyle Teaching Award from the HMS Department of Psychiatry, the MGH Department of Psychiatry's Award for Exceptional Mentorship in the Clinical Realm, a Lifetime Achievement Award from the Society of Liaison Psychiatry, and the Thomas P. Hackett Award from the ACLP (its highest honor).
Joan A. Camprodon Chief, Division of Neuropsychiatry, Director, Transcranial Magnetic Stimulation Clinical Service, Director, Laboratory for Neuropsychiatry & Neuromodulation, Associate Professor of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Dr. Camprodon is board-certified in Psychiatry, and Behavioral Neurology & Neuropsychiatry. His research (as Director of the Laboratory for Neuropsychiatry and Neuromodulation) uses multimodal combinations of neuroimaging and brain stimulation to investigate neural circuitry and plasticity in a translational manner. His lab works with a wide range of noninvasive and invasive neuromodulation techniques including transcranial electrical current stimulation (tECS), transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT) and deep brain stimulation (DBS) among others. The scope of his research includes basic, translational and clinical projects focused on circuit neuroscience. Maurizio Fava Psychiatrist-In-Chief, Department of Psychiatry; Director, Division of Clinical Research, Mass General Research Institute; Executive Director, Clinical Trials Network & Institute; Associate Dean for Clinical & Translational Research, Slater Family Professor of Psychiatry, Harvard Medical School; Massachusetts General Hospital, Boston, Massachusetts. Dr. Maurizio Fava obtained his MD from University of Padova School of Medicine (residency in endocrinology); he completed residency training in psychiatry at the Massachusetts General Hospital (MGH). He founded and was director of the hospital's Depression Clinical and Research Program (DCRP) from 1990 to 2014. In 2007, he founded and is now Executive Director of the MGH Clinical Trials Network and Institute (CTNI), the first academic CRO specialized in planning and coordination of multi-center clinical trials in psychiatry. Under Dr. Fava's direction, the DCRP became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work. His prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression, and of the RAPID Network, the NIMH-funded series of studies of novel, rapidly acting antidepressant therapies. Dr. Fava is a world leader in the field of depression. He has authored or co-authored more than 900 original articles published in medical journals with international circulation, edited eight books, and has been successful in obtaining funding as principal or co-principal investigator from both the National Institutes of Health and other sources for a total of more than $150 million.
